<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35442522</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2053-1095</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Veterinary medicine and science</Title>
          <ISOAbbreviation>Vet Med Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Questionnaire survey on the usage of antiseizure drugs for dogs and cats in Japanese veterinary hospitals (2020).</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/vms3.810</ELocationID>
        <Abstract>
          <AbstractText>Epilepsy is the most common neurological disorder in veterinary medicine. Recently, evidence-based recommendations or systematic reviews for using antiseizure drugs (ASDs) in dogs and cats have been published, but there are many differences in economic, geographical, and historical backgrounds and/or the availability of each ASD between countries. In the present study, we conducted a questionnaire survey on the usage of ASDs in 511 veterinary hospitals in Japan in 2020. As a result, zonisamide (ZNS) was the most commonly prescribed drug for idiopathic (83%) and structural epilepsy (76%) in dogs. In cats, phenobarbital was the most frequently prescribed drug for idiopathic (48%) and structural epilepsy (51%), but ZNS was also commonly prescribed (41% and 36%, respectively). Additionally, ZNS was the most frequently used ASD in combination therapy for canine idiopathic epilepsy. We also surveyed the frequency of measuring ASD blood levels; however, a relatively high percentage of hospitals (22%) did not perform such measurements. Although the evidence level for ZNS is still poor for both species, it is generally used as the first-line ASD in Japan. A large-scale and higher evidential study for ZNS and the education of practitioners for adequate antiseizure medication are required.</AbstractText>
          <CopyrightInformation>Â© 2022 The Authors. Veterinary Medicine and Science published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mizuno</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-2595-5482</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Veterinary Radiology, Nippon Veterinary and Life Science University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asada</LastName>
            <ForeName>Rikako</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-5080-2998</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Veterinary Radiology, Nippon Veterinary and Life Science University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hasegawa</LastName>
            <ForeName>Daisuke</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-7554-9108</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Veterinary Radiology, Nippon Veterinary and Life Science University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Research Center for Animal Life Science, Nippon Veterinary and Life Science University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Vet Med Sci</MedlineTA>
        <NlmUniqueID>101678837</NlmUniqueID>
        <ISSNLinking>2053-1095</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35442522</ArticleId>
        <ArticleId IdType="doi">10.1002/vms3.810</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
